AT 121 | Astraea Therapeutics | United States

Astraea Therapeutics

Discoveries for better health

Astraea Therapeutics is a discovery-stage pharmaceutical company, focused on the development of small-molecule therapeutics for the treatment of drug addiction and central nervous system disorders.

AT-121 in the Spotlight

STM AT-121.jpg

Science Translational Medicine

Cover Story: No Pain, all gain

"AT-121, a small molecule agonist of two opioid receptors, mediates analgesia without opioid-associated side effects in nonhuman primates"

"Rhesus monkeys given AT-121 experienced 100-fold greater pain relief than the same dose of morphine provided"

A Promising Alternative to Opioid Pain Medications

"[AT-121] represents a potential advance toward the goal of nonaddicting analgesics that are at least as effective as opioids but without typical opioid liabilities"

"Nonaddictive Opioid Alternative Shows Promise in Monkey Study"

"Opioid Crisis: breakthrough in hunt for non-addictive painkiller"

Scientific American

"A still-experimental drug demonstrates the qualities of an ideal painkiller in a test in monkeys"

Dr. Nurulain T. Zaveri, PhD.

President and Chief Scientific Officer

Development Pipeline

Click on a project for more information

Contact Us

320 Logue Avenue

Mountain View, CA 94043

650-254-0786

@AstraeaRx